Iq-ai Share Discussion Threads

[howdlep] 27/4/2022 13:48

Latest IQAI tweet:-



Up and running with another trial of @IQAI_IB's IB Clinic. IB Clinic automatically generates quantitative MR DSC perfusion (sRCBV) and Delta T1 (patent-pending) maps to assess neuro disorders. Being able to directly compare changes between scans helps guide treatment decisions.

[howdlep] 27/4/2022 08:34

meanwhile the last two trades yesterday were a £9,900 rollover or Bed & ISA.

Let's wait for the Finals and more importantly for me, the third quarterly letter to shareholders, which is likely today or tomorrow. This will act as a trading update and forward looking statement. However, it could be argued that the Finals will cover the latter, although maybe not in as greater detail. It will be interesting to see which comes first.

[festario] 27/4/2022 08:23

(and idiot)

[festario] 26/4/2022 17:20

Plenty of stock dumped near the close today.Doesn't bode well.No momentum, no move towards any kind of uptrend.I'm wondering, in the absence of any RNSs, why anyone thinks the annual results would be positive. There's been nothing to suggest it whatsoever.We all know how much Trevor likes to ramp when there's even a faint glimmer ... but there's been none of that.

[spurs90] 25/4/2022 15:07

IB Neuro's advanced MR imaging has been shown repeatedly to distinguish tumor from treatment using MRI data alone. Automated & quantitative, enables direct longitudinal comparison too.

PET superior to MRI for meningioma treatment planning via
@AuntMinnie

[clocktower] 25/4/2022 10:39

In todays market its nice to see a bit of decent support at long last.

[cliffv69] 25/4/2022 10:32

Company year accounts this week. I expect a significant rerate once announced. Dyor

[klump] 22/4/2022 12:41

Fest

Remember PET ?

[festario] 22/4/2022 12:02

How's SNG working out for you?When I get my calls as wrong as you do, then I'll start worrying.

[chesty1] 22/4/2022 11:30

Rock Star22 Apr '22 - 09:58 - 316 of 317
0 0 0
Waiting for Annual Results any day now.

I wouldn't go wishing for anything big!!!!

[howdlep] 22/4/2022 10:46

Yes they are due based on last years release date. However, there is no legal requirement to do so yet, so it will be interesting to see whether they release the third quarterly letter to shareholders first. That is due next week.

[rock star] 22/4/2022 09:58

Waiting for Annual Results any day now.

[howdlep] 22/4/2022 07:22

A further IQAI tweet out overnight:-

Impressive application of @IQAI_IB platforms IB Neuro and IB DCE into channel partner
@MedimSight's automated processing pipeline! Great to see the continued and increasing data analysis!

Looks like we are stepping up the PR ahead of the imminent quarterly letter to shareholders.

[bad gateway] 21/4/2022 20:26

Thanks howd, appreciated.

[howdlep] 21/4/2022 16:53

Proactive interview now out re IB progress and Phase I brain cancer study



If the link is removed then view interview from either Twitter or LSE.

[spurs90] 20/4/2022 16:33

Tweet

Great seeing a spike in sales for LSN software!
@IQAI_IB
distributes Liver Surface Nodularity - a noninvasive way to assess chronic liver disease.

[bad gateway] 12/4/2022 13:05

Expected the same to be honest but hey ho pip and dandy looks like we'll have to wait for the market to wake up to these. Perhaps once they've been given orphan drug status the market will notice.

[bad gateway] 12/4/2022 12:43

Another take on the cancer trial, much the same as above but good to see the addition of..

“The discovery that GaM has anticancer activity against glioblastoma in pre-clinical studies is extremely exciting; it opens the door for developing it as a drug for treatment of glioblastoma in patients,” says Christopher Chitambar, MD, Emeritus Professor of Medicine and Biophysics, Division of Hematology and Oncology at MCW. “The anticancer mechanism of GaM applies to other solid tumors as well,” he adds."

(from rat brain trial)


Progress Advances on Innovative Therapy That “Tricks” and Destroys Cancer Cells

[spurs90] 11/4/2022 15:52

Iqai tweet

Nice recognition for Kathleen Schmainda PhD,
@aimbe
Fellow, and her involvement in the Phase I Clinical Trial by The American Institute for Medical and Biological Engineering.